Printer Friendly

BIOGEN ANNOUNCES APPOINTMENT OF MICHAEL J. ASTRUE AS VICE PRESIDENT AND GENERAL COUNSEL

 CAMBRIDGE, Mass., June 3 /PRNewswire/ -- Biogen Inc. (NASDAQ-NMS; BGEN), today announced that Michael J. Astrue has been appointed vice president and general counsel. Astrue will join the company effective July 1, 1993. He replaces Daniel A. Cuoco, who resigned.
 Astrue was most recently a member of Mintz Levin Cohn Ferris Glovsky & Popeo, where he also served as a managing director of ML Strategies. Previously, he pursued a career in U.S. government service.
 Jim Vincent, Biogen's chairman, commented, "We are delighted that Mike Astrue is joining Biogen. Mike has a significant track record in the public sector, with special expertise in areas of law relating to the complex and changing healthcare environment. These areas will play a significant role in Biogen's growth during the coming years. As a member of Mintz Levin, he was among the first-class legal team that works closely with Biogen and that continues to play an integral role in our company's growth and development.
 Astrue was general counsel to the Department of Health and Human Services from 1989 to 1992, reporting to HHS Secretary Louis Sullivan. He supervised the areas of ethics, legislation, civil rights, and business and administrative law. The legal departments of the Food and Drug Administration, Public Health Service, Social Security Administration and Health Care Financing Administration reported to him. From 1988-1989, Astrue was associate counsel to the president. In this capacity, he advised and represented the President and senior White House officials and assisted with criminal and civil litigation involving the Executive Office. From 1986-1988, he was counselor to the commissioner of the Social Security Administration. From 1985-1986, he was acting deputy assistant secretary for Human Services Legislation.
 Before beginning his government career, Astrue was a law clerk for The Honorable Walter J. Skinner and an associate with Ropes & Gray in Boston. He is a graduate of Yale University and the Harvard Law School.
 Biogen, Inc. headquartered in Cambridge, Mass., is a biopharmaceutical company principally engaged in developing and manufacturing drugs for human healthcare through genetic engineering. The company's revenues are generated from the worldwide sales by licensees of five products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen is focused primarily on developing and testing products for the treatment of cardiovascular disease, inflammatory diseases, AIDS, and certain cancers.
 -0- 6/3/93
 /CONTACT: (media) Kathryn R. Bloom, director of communications, 617-252-9851; or (investment community) Amy S. Hedison, director, investor relations, 617-252-9873, both of Biogen, Inc./
 (BGEN)


CO: Biogen, Inc. ST: Massachusetts IN: MTC SU: PER

DD -- NE009 -- 4924 06/03/93 11:07 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 3, 1993
Words:426
Previous Article:KOHL'S CORPORATION FIRST QUARTER EARNINGS REPORT
Next Article:PRODIGY WILL BE NATIONAL LINK BETWEEN INTERACTIVE CONTENT PRODUCERS AND CABLE OPERATORS
Topics:


Related Articles
BIOGEN APPOINTS LAWRENCE S. DANIELS VICE PRESIDENT-MARKETING AND BUSINESS DEVELOPMENT
BIOGEN APPOINTS ALPHONSE R. NOE AS CHIEF INTELLECTUAL PROPERTY COUNSEL
BIOGEN APPOINTS THOMAS J. BUCKNUM AS CHIEF CORPORATE COUNSEL AND ASSOCIATE GENERAL COUNSEL
Biogen Appoints Thomas J. Bucknum as Vice President-General Counsel and Secretary, Replacing Michael J. Astrue.
Maxygen Appoints George Poste to its Board of Directors and Announces Additions to Senior Management.
Michael Astrue Elected Chair of New MBC Directorate for 2000 - 2002.
ArQule Announces Appointments of Vice President, Strategic Development and Vice President, Legal.
Biogen and SurroMed Announce Collaborative Research Agreement for Comprehensive Phenotyping and Biological Marker Discovery; Research Program to...
ArQule Announces Appointment of Michael J. Astrue to the Board of Directors.
SurroMed Announces Extension of Collaborative Research Agreement with Biogen Idec for Comprehensive Biological Marker Discovery.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters